GOSS vs. MCRB, PRQR, CAPR, SKYE, PRLD, GLSI, SCPH, IXHL, CRVO, and IVA
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Seres Therapeutics (MCRB), ProQR Therapeutics (PRQR), Capricor Therapeutics (CAPR), Skye Bioscience (SKYE), Prelude Therapeutics (PRLD), Greenwich LifeSciences (GLSI), scPharmaceuticals (SCPH), Incannex Healthcare (IXHL), CervoMed (CRVO), and Inventiva (IVA). These companies are all part of the "pharmaceutical preparations" industry.
Gossamer Bio (NASDAQ:GOSS) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.
81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 5.0% of Gossamer Bio shares are owned by company insiders. Comparatively, 5.1% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Gossamer Bio has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.
Gossamer Bio presently has a consensus target price of $7.65, suggesting a potential upside of 947.95%. Seres Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 440.89%. Given Gossamer Bio's higher probable upside, equities analysts clearly believe Gossamer Bio is more favorable than Seres Therapeutics.
In the previous week, Gossamer Bio had 19 more articles in the media than Seres Therapeutics. MarketBeat recorded 23 mentions for Gossamer Bio and 4 mentions for Seres Therapeutics. Gossamer Bio's average media sentiment score of 0.41 beat Seres Therapeutics' score of 0.29 indicating that Gossamer Bio is being referred to more favorably in the media.
Seres Therapeutics' return on equity of 0.00% beat Gossamer Bio's return on equity.
Seres Therapeutics has higher revenue and earnings than Gossamer Bio. Seres Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Seres Therapeutics received 380 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 72.48% of users gave Seres Therapeutics an outperform vote while only 65.16% of users gave Gossamer Bio an outperform vote.
Summary
Seres Therapeutics beats Gossamer Bio on 10 of the 16 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
